Matches in Nanopublications for { ?s ?p "[DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1293570.RAcMNIjnj4yfbdFsn09WSGYaJUxDCp4ie-FJHOouPIMUU130_assertion description "[DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293570.RAcMNIjnj4yfbdFsn09WSGYaJUxDCp4ie-FJHOouPIMUU130_provenance.
- NP1293569.RAy1a3PzExAiD9vj-R9yKz8XaYpF2Y8wHq5Fgj7XJ2r-U130_assertion description "[DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293569.RAy1a3PzExAiD9vj-R9yKz8XaYpF2Y8wHq5Fgj7XJ2r-U130_provenance.